Catalent's Maryland Facility To Provide Manufacturing Support For AstraZeneca's COVID-19 Vaccine

(RTTNews) - Catalent, Inc. (CTLT) announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford's COVID-19 vaccine, AZD1222, at Catalent's commercial gene therapy manufacturing facility located in Harmans, Maryland. Catalent's state-of-the-art Harmans/BWI commercial manufacturing facility is equipped with single-use technology, and houses over 200,000 square feet of late-stage clinical and commercial-stage gene therapy production.

Catalent agreed in June that the company's facility in Anagni, Italy, will provide large-scale vial filling and packaging of AZD1222.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.